Navigation Links
Catalyst Pharmaceutical Partners to Present at the MoneyShow Conference
Date:5/7/2010

CORAL GABLES, Fla., May 7 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced that Jack Weinstein, Catalyst's Chief Financial Officer, will be making a presentation at the MoneyShow Conference to be held May 10th through May 13th at Caesars Palace in Las Vegas.  Catalyst will present a Corporate Overview, including its development plans for CPP-109 and CPP-115. Further, the Company reported that its presentation materials from the conference will be posted on May 11th on the Company's website under "Events and Presentations."

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction, epilepsy and neuropathic pain. Catalyst has two products in development, and is currently evaluating the lead product candidate, CPP-109 (vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction, which indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address an unmet medical need. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. Catalyst is also in the early stages of developing CPP-115, another GABA aminotransferase inhibitor that could be more po
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Catalyst Pharmaceutical Partners Regains Compliance with NASDAQ Minimum Bid Price Rule
2. Catalyst Pharmaceutical Partners to Present at the BioNetwork East 2010 Conference
3. Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference
4. Catalyst Pharmaceutical Partners Selected to Present at Epilepsy Conference Highlighting New and Promising Therapies
5. IDEXX Laboratories Announces Catalyst Dx(R) Placement Total for 2009 and Installed Base of SmartService(TM) Customers
6. Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
7. Catalyst Pharmaceutical Partners, Inc. Announces Organizational Changes and Extension of Chief Executives Employment Agreement
8. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
9. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
10. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
11. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. (NYSE ... closing of its offering of $125 million aggregate principal ... "Notes").  The Notes were offered and sold only to ... Securities Act of 1933, as amended (the "Securities Act"). ... rate of 3.75% per year, payable semiannually in arrears ...
(Date:12/17/2014)... and RALEIGH, N.C. , Dec. ... LLC (CTMC), and Integrated Clinical Trial Services, LLC ... retention for clinical trials announce that they have ... Marketing Services (i-CTMS). i-CTMS will provide a broad ... pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... Registreer nu via  http://bit.ly/ag8Sypm14de ... Februar sind alle akkreditierten pharmazeutischen Patientenversorgungsakten-Firmen (PMR) ... PROGRAMM ™ 2015 in Amsterdam ... Tagung soll dazu beitragen, der Aegate PMR ... profitablen Unternehmensdienstleistungen, die für Apotheken und die ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... , , , , FRAZER, Pa., Jan. ... that effective February 5, 2010, Robert P. Roche, Jr., Executive ... with the company to pursue other longstanding interests. During ... and marketing organization into a global business that exceeded $2 ...
... , SOUTH SAN FRANCISCO, Dec. 31 ... was unable to satisfy the closing conditions set forth in ... among Anesiva, Arca Acquisition Corporation, a wholly-owned subsidiary of Anesiva, ... and IX only of the agreement, each of the Arcion ...
Cached Medicine Technology:Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position 2Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position 3Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position 4Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed 2
(Date:12/19/2014)... The Plantrician Project , a ... tools and resources for healthcare professionals and their ... world’s leading online cooking school, have joined forces ... Culinary Rx. As an online food and nutrition ... for debut spring 2015, will be designed to ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Eufaula, Oklahoma, ... to Lake Eufaula, the state’s largest lake with more ... town is home to a little more than 3,000 ... P.M. on Saturday, the 6th of December. , Featuring ... way through downtown Eufaula on Main Street. Narconon ...
(Date:12/19/2014)... Abilene, TX (PRWEB) December 20, 2014 ... XC, a new injectable filler from respected cosmetic brand ... can occur naturally with age. The Medspa at Hendrick ... new development in skin care technology to its clients. ... filler gel to be FDA-approved to treat the mid-face ...
(Date:12/19/2014)... The intestinal bacteria that cause inflammatory bowel disease, which ... researchers report. The findings, published recently in the ... to prevent the disease and treat the 1.6 million ... "The intestinal bacteria, or ,gut microbiome, you develop ... impact on your health for the rest of your ...
(Date:12/19/2014)... -- Injectable drug users who also use cocaine and ... other substance users, a new study finds. "We ... of suicide attempt and completed suicide," Didier Jutras-Aswad, a ... a university news release. "However, there are many different ... among substance users were actually more likely to attempt ...
Breaking Medicine News(10 mins):Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2
... In keeping with its,commitment to wellness, and following ... Michigan, a leading HMO in the state, is building ... employees at the,workplace., BCN, which is the HMO ... year instituted Wellness Works!, an employee health,and fitness program ...
... Larry Kocot and Robert,Seidman Headline Agenda at FDA/CMS ... medicine has,progressed beyond a topic of industry insider ... public and private payers. Value isn,t a new,concept ... mean for buying and,selling biopharmaceuticals? How is value ...
... FDA Approval, Agreement will Broaden Access to ... Cholesterol-Reducing Medicine, ... USA (GSK) and Merck & Co., Inc.,Whitehouse Station, NJ, USA ... over-the-counter (OTC) marketing rights for,MEVACOR(R) (lovastatin). Under the agreement, GSK ...
... N.J., Nov. 26 Pharmasset, Inc.,(Nasdaq: VRUS ... President,Marketing & Sales, responsible for coordinating the global ... Mr. Higgins, who,has served as a consultant to ... Marketing, Virology at Hoffmann-LaRoche, Inc. His areas,of expertise ...
... also hinder progress, study finds , MONDAY, Nov. 26 ... ("good") cholesterol increase the risk of memory problems and ... , The study also found that high levels of ... meat, also boosts post-stroke disability. , "People with low ...
... prevent osteoporosis, researchers say , , MONDAY, Nov. 26 (HealthDay News) ... than do non-depressed women in the same age range, a ... pronounced in certain regions of the hip, which is troubling ... -- and potentially fatal -- consequences of osteoporosis. , ...
Cached Medicine News:Health News:Leading by Example: Blue Care Network of Michigan Shows How Employers Can Improve Employee Wellness 2Health News:Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace 2Health News:Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace 3Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 2Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 3Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 4Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 5Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 6Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 7Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 8Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 9Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 10Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 11Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 12Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 13Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 14Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 15Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 16Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 17Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 18Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 19Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 20Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 21Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 22Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 23Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 24Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 25Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 26Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 27Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 28Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 29Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 30Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 31Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 32Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 33
Inquire...
... dilate the lower ureter and ... possible submucosal tunneling. Also used ... in the ureter. The tapered ... dislodgment of a ureteral stone. ...
Used for drainage and retrograde pyelogram. The spiral tip aids in negotiation of a tortuous or partially obstructed ureter. Supplied sterile in peel-open packages. Intended for one-time use....
... Used for the injection of contrast ... The dual lumen design eliminates the need ... designed to promote atraumatic passage into and ... layer of hydrophilic polymer that when activated, ...
Medicine Products: